Gómez-Hernández FA, Sampieri A, Carmona-Aparicio L

Language: Spanish
References: 9
Page: 171-172
PDF size: 152.76 Kb.

Text Extraction

No abstract.

REFERENCES

1. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-62.

2. Routh JI, Bannow RE, Fincham RW, Stoll JL. Excretion of L-dopa and its metabolites in urine of Parkinson’s disease patients receiving L-dopa therapy. Clin Chem. 1971;17(9):867- 71.

3. Molenaar WM, Jansson DS, Gould VE, Rorke LB, Franke WW, Lee VM, Packer RJ, Trojanowski JQ. Molecular markers of primitive neuroectodermal tumors and other pediatric central nervous system tumors. Monoclonal antibodies to neuronal and glial antigens distinguish subsets of primitive neuroectodermal tumors. Lab Invest. 1989;61(6):635-43.

4. Hartley SG, Goodman HO, Shihabi Z. Urinary excretion of taurine in epilepsy. Neurochem Res. 1989;14(2):149-52.

5. Carmona-Aparicio L, Peña F, Borsodi A, Rocha L. Effects of nociceptin on the spread and seizure activity in the rat amygdala kindling model: their correlations with 3H-leucyl-nociceptin binding. Epilepsy Res. 2007;77(2-3):75-84.

6. Carmona Aparicio L, Candeletti S, Binaschi A, Mazzuferi M, Mantovani S, Di Benedetto M, Landuzzi D, Lopetuso G, Romualdi P, Simonato M. Kainate seizures increase Nociceptin/ Orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. J Neurochem. 2004;91(1):30-7.

7. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302(5646):830-4.

8. Berg D. Biomarkers for the early detection of Parkinson’s and Alzheimer’s disease. Neurodegener Dis. 2008;5(3-4):133-6.

9. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009;35(2):65-76.